187 related articles for article (PubMed ID: 16393291)
1. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.
Brunner M; Assandri R; Kletter K; Tschurlovits M; Corrado ME; Villa R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2003 Feb; 17(3):395-402. PubMed ID: 12562452
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers.
Brunner M; Greinwald R; Kletter K; Kvaternik H; Corrado ME; Eichler HG; Müller M
Aliment Pharmacol Ther; 2003 May; 17(9):1163-9. PubMed ID: 12752353
[TBL] [Abstract][Full Text] [Related]
4. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release.
Foppoli A; Maroni A; Moutaharrik S; Melocchi A; Zema L; Palugan L; Cerea M; Gazzaniga A
Int J Pharm; 2019 Dec; 572():118723. PubMed ID: 31628978
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of controlled release mesalazine (5-ASA) preparations.
Rasmussen SN
J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
[TBL] [Abstract][Full Text] [Related]
6. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
Tenjarla S
Drugs R D; 2015 Jun; 15(2):211-5. PubMed ID: 26115756
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
Wilding IR; Kenyon CJ; Hooper G
Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
[TBL] [Abstract][Full Text] [Related]
8. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
Healey JN
Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
[TBL] [Abstract][Full Text] [Related]
10. Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.
Varum F; Thorne H; Bravo R; Gilgen D; Hartig C; Nicolas GP; Wild D; Liakoni E; Haschke M
Int J Pharm; 2022 Sep; 625():122055. PubMed ID: 35926752
[TBL] [Abstract][Full Text] [Related]
11. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
12. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
Varum FJ; Hatton GB; Freire AC; Basit AW
Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
[TBL] [Abstract][Full Text] [Related]
13. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa F; Klein S
J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
[TBL] [Abstract][Full Text] [Related]
14. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system.
Tenjarla S; Romasanta V; Zeijdner E; Villa R; Moro L
Adv Ther; 2007; 24(4):826-40. PubMed ID: 17901032
[TBL] [Abstract][Full Text] [Related]
15. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects.
Wilding IR; Behrens C; Tardif SJ; Wray H; Bias P; Albrecht W
Aliment Pharmacol Ther; 2003 May; 17(9):1153-62. PubMed ID: 12752352
[TBL] [Abstract][Full Text] [Related]
16. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
Chuong MC; Christensen JM; Ayres JW
Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
[TBL] [Abstract][Full Text] [Related]
17. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
[TBL] [Abstract][Full Text] [Related]
18. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
19. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
[TBL] [Abstract][Full Text] [Related]
20. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
